Regulus Therapeutics stock holds as clinical data drive valuation

Published on 09/23/2026 at 15:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regulus Therapeutics stock traded at USD 0.44 on September 22, 2026. Its 52-week range spans USD 0.31 to USD 1.42, keeping trial progress central.

RGLS, US7588491032, Illustration mit AI erstellt.

Regulus Therapeutics stock, issued under ISIN US7588491032, traded at USD 0.44 on September 22, 2026. The Nasdaq-listed biotechnology company is valued against a 52-week range of USD 0.31 to USD 1.42, leaving the latest quote USD 0.13 above the low and USD 0.98 below the high.

Clinical progress drives the story

Regulus Therapeutics is a development-stage biotechnology company, so clinical milestones rather than recurring sales remain central to the equity case. The company is working in a sector where trial results can materially change valuation, while the absence of established commercial revenue leaves development execution as the principal operating variable.

The broader bladder-cancer development landscape included a Phase 1/2 study of MK-3120 announced for September 11, 2026, and a Phase 3 study involving enfortumab vedotin and pembrolizumab on the same date, according to OpenPR. Those dates illustrate the competitive setting for development-stage drug companies, although the cited studies are not Regulus programs.

Range leaves valuation sensitive

The September 22, 2026 quote sits 29.5 percent above the 52-week low and 69.0 percent below the 52-week high, based on the same dated market range. That gap is a concrete measure of how strongly the stock's valuation remains tied to clinical expectations rather than established earnings.

For investors, the operating comparison is therefore between a USD 0.44 market price and the company's ability to produce reportable clinical or regulatory milestones. The available market reference supplies the clearest dated signal: the latest price is closer to the annual low than to the annual high, with a USD 0.98 difference to the upper boundary.

Stock remains below yearly high

Regulus Therapeutics stock closed at USD 0.44 on Nasdaq on September 22, 2026. The dated range of USD 0.31 to USD 1.42 and the 29.5 percent premium to the low provide the current market frame for the company.